433289-50-0

Upstream product

• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 
• 589-17-3 p-bromobenzyl chloride 
• 589-15-1 1-bromomethyl-4-bromobenzene 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 

Downstream Products

• 1600530-93-5 (4R)-4-{[4'(diethoxyphosphoryl)benzyl]oxy}-N-Boc-L-proline methyl ester 
• 1600530-94-6 (4R)-4-[(4'-phosphonobenzyl)oxy]-L-proline methyl ester 
• 1600530-95-7 (4R)-4-[(4'-phosphonobenzyl)oxy]-L-proline 
• 848475-20-7 (4R)-4-[(4'-bromobenzyl)oxy]-N-Boc-L-proline methyl ester 
• 757951-17-0 (2S,4R)-4-(4-Bromo-benzyloxy)-pyrrolidine-2-carboxylic acid 

Relevant academic research and scientific papers

Synthesis of zirconium phosphonate supported L-proline as an effective organocatalyst for direct asymmetric aldol addition

Stable L-proline-functionalized zirconium methyl- and/or phenylphosphonates have been prepared as amorphous solids by the precipitation of (4R)-4-[(4′-phosphonobenzyl)oxy]-L-proline and methyl- and/or phenylphosphonic acid with ZrOCl2. The supported L-proline catalysts were tested in the direct asymmetric aldol addition between several ketones and p-substituted benzaldehydes. High yields, diastereoselectivities (anti/syn up to 92:8) and enantiomeric excesses (up to 99 % ee) have been achieved. Moreover, an easy protocol for the efficient recovery of the catalytic system by simple centrifugation has been defined, and the effective reuse of the catalyst has been reported in the representative aldol addition of cyclohexanone with p-nitrobenzaldehyde. This study has shown that these L-proline immobilized catalytic systems can be used at least six times without loss of activity and with reproducible anti/syn and ee values. Copyright

Synthesis of Zirconium Phosphonate Supported L -Proline as an Effective Organocatalyst for Direct Asymmetric Aldol Addition

Stable L-proline-functionalized zirconium methyl- and/or phenylphosphonates have been prepared as amorphous solids by the precipitation of (4R)-4-[(4′-phosphonobenzyl)oxy]-L-proline and methyl- and/or phenylphosphonic acid with ZrOCl2. The supp

Capped dipeptide phenethylamide inhibitors of the HCV NS3 protease

The N-terminal aminoacid of phenethylamide tripeptide inhibitors of the hepatitis C virus NS3 protease can be replaced with an α-hydroxy acid to obtain more 'drug like' inhibitors with low micromolar activity. The preferred S-configuration of the capping

Hydantoin compounds useful as anti-inflammatory agents

Compounds having the formula (I): 1and pharmaceutically-acceptable salts thereof, are useful for treating inflammatory or immune diseases, in which A is a four to seven membered heterocyclic or carbocyclic saturated ring; L and K are O or S; M is N or CH; Y is N or CH; Z is hydrogen, alkyl or substituted alkyl; and R1-R4 are as defined in the specification.